FDA approves 1st COVID-19 drug: the antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health.
Share:
